Ironwood Pharmaceuticals Inc

Latest Ironwood Pharmaceuticals Inc News and Updates

  • uploads///TSRO
    Company & Industry Overviews

    Here’s What Tesaro’s Valuation Trend Indicates

    Tesaro stock has been on a downward trajectory for the past 52 weeks. From a high of $135 on September 5, 2017, it has corrected to $27 in August.

    By Kenneth Smith
  • uploads///NKTR
    Company & Industry Overviews

    What Does Nektar Therapeutics’ Valuation Trend Indicate?

    Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).

    By Kenneth Smith
  • uploads///Sucampo Revenue Growth
    Company & Industry Overviews

    The Financial Performance of Sucampo Pharmaceuticals

    Sucampo Pharmaceuticals (SCMP) generated revenues of $61.2 million in 3Q17 compared with $57 million in 3Q16.

    By Kenneth Smith
  • uploads///VTS
    Company & Industry Overviews

    Sucampo Pharmaceuticals’ Amitiza: Its Competitive Landscape

    In the branded prescription category, Amitiza competes with Ironwood Pharmaceuticals (IRWD) and Allergan’s (AGN) Linzess.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca’s Recent Products: Approvals and Designations

    AstraZeneca’s (AZN) recent product developments include four drugs that have recently received approvals from regulatory authorities. Four other drugs have received regulatory designations.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Will AstraZeneca’s Corporate Developments Help?

    In this part, we’ll look at some of AstraZeneca’s corporate developments. It entered into some collaborative agreements in 1Q16, including drug development and commercialization rights.

    By Mike Benson
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    IBB Small-Caps Reduce Negative Returns in December

    The small-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) rose 1.4% on December 21, 2015, and reduced the negative returns.

    By Peter Neil
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.